As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front of the American people. In a one-minute ad, the direct-to-consumer health company ...

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $36.17, marking a -5.51% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.45%.

BofA raised its HIMS price target to $37 from $36 but kept a 'Neutral' rating, warning that retention among oral Wegovy users ...

Hims & Hers Health has delivered a very large 3 year return, yet the stock still screens as undervalued on market multiples ...

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space. This is bringing a new class of tech-driven innovators to the forefront.

One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical ...

Hims & Hers, the telehealth and wellness company, has hired a veteran of the autonomous vehicle industry as its next chief technology officer. The move, according to Hims & Hers co-founder and CEO ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space. This is bringing a new class of tech-driven innovators to the forefront.